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Introduction {#apt13243-sec-0006}
============

Vedolizumab, a humanised monoclonal antibody that binds specifically to the *α* ~4~ *β* ~7~ integrin, is indicated for the treatment of patients with moderately to severely active ulcerative colitis (UC) and Crohn\'s disease (CD).[1](#apt13243-bib-0001){ref-type="ref"} By binding to cell surface‐expressed α~4~β~7~, vedolizumab blocks the interaction of a subset of memory gut‐homing T lymphocytes with mucosal addressin cell adhesion molecule‐1 (MAdCAM--1) expressed on endothelial cells. Consequently, migration of these cells into inflamed intestinal tissue is inhibited.[1](#apt13243-bib-0001){ref-type="ref"} The specificity of vedolizumab results in a novel gut‐selective mechanism of action that differs from that of other currently marketed biologic agents for the treatment for UC and CD, including natalizumab and tumour necrosis factor‐α (TNF‐α) antagonists.

The pharmacokinetics of other therapeutic monoclonal antibodies used for the treatment of UC and CD have been reported previously.[2](#apt13243-bib-0002){ref-type="ref"} Several factors are associated with accelerated clearance of these antibodies, including the presence of anti‐drug antibodies (ADAs), sex, body size, concomitant immunosuppressant use, inflammatory bowel disease (IBD) type, albumin concentration and degree of systemic inflammation.[3](#apt13243-bib-0003){ref-type="ref"} Furthermore, a consistent relationship between efficacy and exposure, in distinction to drug dose, has been observed for many of these agents; that is, higher trough drug concentrations are associated with greater efficacy.[4](#apt13243-bib-0004){ref-type="ref"} Differences in drug clearance may be an important explanation for this observation. Therefore, a better understanding of the determinants of clearance for therapeutic antibodies may result in optimization of drug dosing regimens.

The single‐dose pharmacokinetics, pharmacodynamics (α~4~β~7~ receptor saturation), safety and tolerability of vedolizumab have been investigated over a dose range of 0.2--10 mg/kg in healthy volunteers (intravenous \[IV\] infusion) (Takeda Pharmaceuticals International, Inc., data on file). After reaching peak concentrations, vedolizumab serum concentrations fell in a generally biexponential fashion until concentrations reached approximately 1--10 ng/mL. Thereafter, concentrations appeared to fall in a nonlinear fashion. The multiple‐dose pharmacokinetics and pharmacodynamics of vedolizumab have been investigated following IV infusions of 0.5 and 2 mg/kg in patients with CD[5](#apt13243-bib-0005){ref-type="ref"} and patients with UC[6](#apt13243-bib-0006){ref-type="ref"} and following IV infusions of 2, 6, and 10 mg/kg in patients with UC.[7](#apt13243-bib-0007){ref-type="ref"} Vedolizumab pharmacokinetics was generally linear following IV infusion over the dose range of 2--10 mg/kg in patients with UC.[7](#apt13243-bib-0007){ref-type="ref"} After multiple‐dose administration, rapid and near complete α~4~β~7~ receptor saturation was achieved following the first dose of vedolizumab in patients with UC.[7](#apt13243-bib-0007){ref-type="ref"}

The efficacy and safety of vedolizumab 300 mg IV induction therapy and vedolizumab 300 mg IV maintenance therapy administered every 8 weeks (Q8W) or every 4 weeks (Q4W) were demonstrated in patients with moderately to severely active UC in the GEMINI 1 trial and in patients with moderately to severely active CD in the GEMINI 2 and 3 trials.[8](#apt13243-bib-0008){ref-type="ref"}, [9](#apt13243-bib-0009){ref-type="ref"}, [10](#apt13243-bib-0010){ref-type="ref"} The exposure‐response (efficacy) relationships of vedolizumab induction and maintenance therapy in these patients have been presented elsewhere.[8](#apt13243-bib-0008){ref-type="ref"}, [9](#apt13243-bib-0009){ref-type="ref"}, [11](#apt13243-bib-0011){ref-type="ref"}, [12](#apt13243-bib-0012){ref-type="ref"}

Here, we report a comprehensive population pharmacokinetic and pharmacodynamic analysis of vedolizumab therapy in patients with UC and CD. Our objectives were to (i) characterise the pharmacokinetics of vedolizumab in patients who received repeated IV infusions of vedolizumab 300 mg for up to 52 weeks; (ii) identify clinically relevant determinants of vedolizumab clearance in patients; and (iii) describe the pharmacokinetic--pharmacodynamic relationship of vedolizumab in patients using MAdCAM‐1 as the pharmacodynamic endpoint.

Materials and methods {#apt13243-sec-0007}
=====================

Study design and sample collection {#apt13243-sec-0008}
----------------------------------

Analyses were conducted using vedolizumab serum concentrations obtained from 5 randomised, placebo‐controlled clinical studies: a phase 1 study in healthy volunteers, a phase 2 study in patients with active UC (NCT01177228), a phase 3 study in patients with moderately to severely active UC \[GEMINI 1 (NCT00783718)\], and 2 phase 3 studies in patients with moderately to severely active CD \[GEMINI 2 (NCT00783692) and GEMINI 3 (NCT01224171)\] (Table S1). The study designs and clinical data for the phase 2 and 3 studies have been previously reported.[7](#apt13243-bib-0007){ref-type="ref"}, [8](#apt13243-bib-0008){ref-type="ref"}, [9](#apt13243-bib-0009){ref-type="ref"}, [10](#apt13243-bib-0010){ref-type="ref"} All study protocols and consent forms were approved by institutional review boards or ethics committees at the study sites, and studies were conducted in accordance with the principles of good clinical practice and the Declaration of Helsinki. All patients provided written informed consent before study participation.

Details of the blood sampling times for pharmacokinetic, pharmacodynamic (MAdCAM‐1), and ADA analyses are provided in Table S1. Extensive pharmacokinetic and pharmacodynamic sampling was used in the phase 1 and 2 studies, whereas sparse sampling was used in the phase 3 studies. Pharmacodynamic samples were not collected in GEMINI 3.

Assays {#apt13243-sec-0009}
------

Vedolizumab serum concentrations were determined using a sandwich enzyme‐linked immunosorbent assay (ELISA), with a lower limit of quantification of 1.25 ng/mL at a 1:100 dilution (125 ng/mL in undiluted serum). The upper limit of quantification was 8 μg/mL; serum samples with vedolizumab concentrations greater than 8 μg/mL were diluted to within the assay range. The assay was validated at Quest Pharmaceutical Services (Newark, DE, USA). The accuracy of the assay ranged from −2.5% to 10.1% difference, intra‐sample precision ranged from 1.8% to 3.1% CV, and inter‐sample precision ranged from 4.0% to 16.2% CV.

To quantitate α~4~β~7~ integrin saturation by vedolizumab in peripheral blood, a MAdCAM--1--Fc binding interference flow cytometry assay was developed. In this pharmacodynamic assay, inhibition of MAdCAM‐1‐Fc binding to α~4~β~7~‐expressing peripheral blood cells by vedolizumab in the blood is used as a measure of the extent of α~4~β~7~ saturation by vedolizumab.[1](#apt13243-bib-0001){ref-type="ref"} The assay, which was developed by Millennium Pharmaceuticals, Inc. (d/b/a Takeda Pharmaceuticals International, Co.) and validated at Esoterix Center for Clinical Trial Research (Brentwood, TN, USA), demonstrated an overall intra‐sample variability of 6% CV and an intra‐subject variability of 20% CV.

The presence of ADAs was determined using a validated, biotinylated, bridging ELISA and 2 dilutions of serum (1:5 and 1:50). All samples that screened positive were further diluted to determine the final ADA titre using standard techniques. If both screening dilutions were negative, the sample was considered negative. Patients were classified as positive for ADAs if antibodies were detected at any visit; otherwise, they were classified as negative.

Data assembly {#apt13243-sec-0010}
-------------

The dosing, covariate and pharmacokinetic‐pharmacodynamic data were merged and formatted for the population analysis using R, Version 2.10.1 or higher (<http://www.r-project.org/>). Vedolizumab serum concentration measurements that were missing, or any values with unknown or missing associated observation times, dose times, dose amounts or dosing intervals, were excluded from the analysis. MAdCAM‐1 measurements were treated similarly. All samples with vedolizumab concentrations below the limit of quantification (BLQ) (*n* = 3189) were not evaluated during the population pharmacokinetic model development. More than half of the BLQ observations (*n* = 1722) were samples obtained prior to the first vedolizumab dose.

Covariates present in the population pharmacokinetic data set were serum C‐reactive protein (CRP), serum albumin, faecal calprotectin, body weight, disease activity \[Crohn\'s Disease Activity Index (CDAI), complete Mayo score, partial Mayo score\], Mayo endoscopic subscore, age, sex, ADA status (positive or negative), prior TNF‐α antagonist therapy status (naïve or failed), body mass index (BMI), serum globulin, IBD diagnosis (CD or UC), lymphocyte count and concomitant therapy use (methotrexate, azathioprine, mercaptopurine or aminosalicylates). The start date and end date of concomitant therapy were populated in the data set to evaluate the time‐dependent effects of concomitant treatments. Covariates with missing data were imputed using different imputation methods, based on the remaining available data (e.g. median of the remaining values). No covariates present in the data set were missing more than 10% of values.

Population pharmacokinetic model development {#apt13243-sec-0011}
--------------------------------------------

The population pharmacokinetic analysis for repeated measures was conducted using a nonlinear mixed effects modelling approach (NONMEM 7, Version 7.2; ICON Development Solutions, Hanover, MD, USA).[13](#apt13243-bib-0013){ref-type="ref"} The base population pharmacokinetic model was developed using the first‐order conditional estimation with *η*‐*ε* interaction (FOCEI) method and extensively sampled phase 1 and 2 data. Results from the base model were subsequently used as prior information to selectively inform a subset of population pharmacokinetic model parameters in the full covariate model, which was fit to sparse phase 3 data from GEMINI 1, 2 and 3 using the full Bayesian Markov Chain Monte Carlo (MCMC) method. All parameter estimates were reported with Bayesian 95% credible intervals (CDIs) as a measure of estimation uncertainty.

A covariate modelling approach emphasising parameter estimation rather than stepwise hypothesis testing was implemented for the population pharmacokinetic analysis.[14](#apt13243-bib-0014){ref-type="ref"} First, predefined covariate‐parameter relationships were identified based on exploratory graphics, scientific interest, and mechanistic plausibility. Then a full covariate model was constructed with care to avoid correlation or collinearity in predictors; covariates with correlation coefficients greater than approximately 0.35 were not simultaneously included as potential predictors. Construction of the full model was also guided by evaluating the adequacy of the study design and covariate data to support quantification of the covariate effects of interest.

During development of the covariate model, strong correlations were identified between the following covariates: body weight--BMI, sex--body weight, CRP--albumin, CRP--faecal calprotectin, CRP--globulin, albumin--globulin, complete Mayo score--partial Mayo score, Mayo endoscopic subscore--complete Mayo score, and Mayo endoscopic subscore--partial Mayo score. Therefore, sex, CRP, complete Mayo score, Mayo endoscopic subscore, globulin, and BMI were excluded from the full covariate model. As the effects of sex, CRP, and Mayo endoscopic subscore on the pharmacokinetics of vedolizumab could not be uniquely estimated in the full model given their correlation with other covariates, any remaining effects of these covariates were independently evaluated in an exploratory *post hoc* fashion once the population pharmacokinetic model was finalised.

Body weight was chosen to represent changes in vedolizumab pharmacokinetics as a function of body size and was described using an allometric model with a reference weight of 70 kg. The other continuous covariates of albumin, faecal calprotectin, partial Mayo score, age, and CDAI score entered the model as power functions normalised by a reference value. The categorical covariates of prior TNF‐*α* antagonist therapy status, ADA status, concomitant therapy use, and IBD diagnosis entered the model as power functions, with a separate dichotomous (0, 1) covariate serving as an on‐off switch for each effect. Time‐dependent covariates were body weight, albumin, faecal calprotectin, and concomitant therapy use. The effect of IBD diagnosis on linear clearance (*CL* ~L~) was investigated by modelling separate *CL* ~L~ parameters for patients with UC and those with CD, while the effect of IBD diagnosis on central compartment volume of distribution (*V* ~c~) was evaluated by including diagnosis as a predictor of *V* ~c~ in the covariate model.

Inferences about the clinical relevance of parameters were based on the resulting parameter estimates and measures of estimation precision (Bayesian 95% CDIs) from the full model. In the absence of an exposure‐response relationship for efficacy‐related clinical endpoints to provide a context for interpretation of pharmacokinetic variability, covariate effect sizes on *CL* ~L~ greater than ± 25% of the normalised reference value were proposed as clinically meaningful changes.

Further details regarding the population pharmacokinetic and pharmacodynamic analysis methods, including modelling assumptions and model evaluation, are provided in Appendix S1.

Population pharmacokinetic‐pharmacodynamic model development {#apt13243-sec-0012}
------------------------------------------------------------

The population pharmacokinetic‐pharmacodynamic analysis for repeated measures was conducted using a nonlinear mixed effects modelling approach (NONMEM, Version 7.2).[13](#apt13243-bib-0013){ref-type="ref"} The pharmacokinetic‐pharmacodynamic data were modelled using a sequential approach, where individual predicted vedolizumab serum concentrations from the population pharmacokinetic model were used to drive the pharmacodynamic response. The pharmacodynamic evaluations were based on percentage of MAdCAM‐1 binding by lymphocytes expressing high levels of α~4~β~7~ integrin (CD4^+^ CD45RO^high^).

A direct effect sigmoid *E* ~max~ model was chosen as the structural model to describe the pharmacokinetic‐pharmacodynamic relationship of vedolizumab as follows:$$\text{MAdCAM‐1} = E_{0} \times \left( {1 - \frac{E_{\max} \times \text{Conc}^{\gamma}}{\text{EC}_{50}^{\gamma} + \text{Conc}^{\gamma}}} \right)$$where *E* ~0~ is the baseline MAdCAM‐1 percent binding, *E* ~max~ is the maximum effect, Conc is the vedolizumab serum concentration, *EC* ~50~ is the vedolizumab serum concentration at half‐maximum effect, and γ is the Hill‐coefficient or slope factor. No formal covariate modelling or model evaluation was conducted.

Results {#apt13243-sec-0013}
=======

Pharmacokinetic analysis data set {#apt13243-sec-0014}
---------------------------------

The pharmacokinetic analysis data set consisted of 2554 individuals who contributed 18 427 evaluable vedolizumab serum samples, including 87 healthy volunteers from the phase 1 study, 46 patients from the phase 2 study (UC), and 891, 1115, and 415 patients from the phase 3 GEMINI 1 (UC), GEMINI 2 (CD), and GEMINI 3 (CD) studies, respectively.

Demographics and other characteristics of the pharmacokinetic analysis data set are summarised in Table [1](#apt13243-tbl-0001){ref-type="table-wrap"}. The data set consisted of 1290 men and 1264 women with ages ranging from 18 to 78 years and baseline body weights ranging from 28 to 170 kg. A total of 1530 individuals had CD and 937 had UC; 87 were healthy volunteers.

###### 

Summary of demographics and other characteristics of the pharmacokinetic analysis data set (*N* = 2554)

  Categorical covariate                            *n* (%)
  ------------------------------------------------ -----------
  Sex                                              
  Women                                            1264 (50)
  Men                                              1290 (50)
  Disease diagnosis                                
  Crohn\'s disease                                 1530 (60)
  Ulcerative colitis                               937 (37)
  Healthy volunteers                               87 (3)
  Mayo Endoscopic Subscore                         
  1                                                1 (0.039)
  2                                                408 (16)
  3                                                482 (19)
  Missing[a](#apt13243-note-0003){ref-type="fn"}   1663 (65)
  Prior TNF‐α antagonist therapy status            
  Failed                                           1321 (52)
  Naïve                                            1100 (43)
  Missing[b](#apt13243-note-0004){ref-type="fn"}   133 (5)
  ADA status                                       
  Positive (≥1 positive titre)                     124 (5)
  Negative (no positive titres)                    2430 (95)

  Continuous covariate         *n*    Median (range)
  ---------------------------- ------ ---------------------
  Age, years                   2554   36 (18--78)
  Body weight, kg              2554   68 (28--170)
  Albumin, g/L                 2467   37 (11--53)
  C‐reactive protein, mg/L     1576   11 (0.2--200)
  Faecal calprotectin, mg/kg   2421   720 (23.75--20 000)
  CDAI score                   1530   320 (93--580)
  Mayo Score                   891    9 (3--12)
  Partial Mayo Score           937    6 (1--9)

ADA, anti‐drug antibody; CDAI, Crohn\'s Disease Activity Index; TNF‐*α*, tumour necrosis factor‐*α*.

Data not collected in phase 1 and 2 studies or in GEMINI 2 and 3 studies.

Data not collected in phase 1 and 2 studies.

John Wiley & Sons, Ltd

The median (interquartile range) vedolizumab trough serum concentration‐time profiles for patients with UC from GEMINI 1 and patients with CD from GEMINI 2 are shown in Figure [1](#apt13243-fig-0001){ref-type="fig"}.

![Median (interquartile range) of observed vedolizumab trough serum concentration vs. nominal sampling time in patients with UC (GEMINI 1) and patients with CD (GEMINI 2) during maintenance treatment with placebo or vedolizumab 300 mg every 4 weeks (Q4W) or every 8 weeks (Q8W). All patients (including those in the placebo group) received 2 doses of vedolizumab 300 mg during induction (at weeks 0 and 2). The median value is shown as a point and the interquartile range is represented by a vertical bar.](APT-42-188-g001){#apt13243-fig-0001}

Population pharmacokinetic modelling results {#apt13243-sec-0015}
--------------------------------------------

### Base pharmacokinetic model {#apt13243-sec-0016}

Vedolizumab pharmacokinetics was described by a 2--compartment model with parallel linear and nonlinear elimination. A 2‐compartment model resulted in a significant improvement in goodness‐of‐fit criteria over a 1--compartment model, as did a parallel linear and nonlinear elimination model over a linear model. The population pharmacokinetic model of vedolizumab is represented diagrammatically in Figure [2](#apt13243-fig-0002){ref-type="fig"}.

![Diagrammatic representation of the population pharmacokinetic model of vedolizumab. Conc, vedolizumab concentration; *K* ~m~, concentration at half‐maximum elimination rate; *V* ~max~, maximum elimination rate.](APT-42-188-g002){#apt13243-fig-0002}

### Final pharmacokinetic model {#apt13243-sec-0017}

Pharmacokinetic parameter estimates and 95% CDIs from the final population pharmacokinetic model are shown in Table [2](#apt13243-tbl-0002){ref-type="table-wrap"}, and their interindividual variability estimates are shown in Table S2. The parameter estimates and overlapping 95% CDIs indicated that vedolizumab *CL* ~L~ was the same in patients with UC (0.159 L/day) and those with CD (0.155 L/day). Individual *CL* ~L~ estimates were distributed over a wide range as represented in Figure [3](#apt13243-fig-0003){ref-type="fig"}. The half‐life of vedolizumab for the linear elimination phase was 25.5 days; individual estimates ranged from 14.6 to 36.0 days (5th and 95th percentiles, respectively). Interindividual variability estimates (% CV) from the model were 34.6% for *CL* ~L~ and 19.1% for *V* ~c~, indicative of moderate to large unexplained variability (Table S2).

###### 

Parameter estimates from the final population pharmacokinetic model for vedolizumab

  Parameter                                                  Estimate[a](#apt13243-note-0006){ref-type="fn"}   Bayesian 95% CDI
  ---------------------------------------------------------- ------------------------------------------------- ------------------
  Ulcerative colitis: *CL* ~L~                               0.159 L/day                                       0.153--0.165
  Crohn\'s Disease: *CL* ~L~                                 0.155 L/day                                       0.149--0.161
  Central compartment volume of distribution (*V* ~c~)       3.19 L                                            3.14--3.25
  Peripheral compartment volume of distribution (*V* ~p~)    1.65 L                                            1.59--1.71
  Intercompartmental clearance (*Q*)                         0.12 L/day                                        0.112--0.129
  Maximum elimination rate (*V* ~max~)                       0.265 mg/day                                      0.219--0.318
  Concentration at half‐maximum elimination rate (*K* ~m~)   0.964 μg/mL                                       0.706--1.27
  Proportional residual error variance (σ^2^ ~prop~)         0.0554 (% CV = 23.5)                              0.0539--0.0568

CDI, credible interval; *CL* ~L~, clearance of linear elimination pathway; CV, coefficient of variation.

Parameter estimate and 95% credible interval were derived from the median and 2.5th and 97.5th percentiles, respectively, of the Bayesian posterior probability distributions from 4 Markov Chain Monte Carlo chains. Separate values of *CL* ~L~ were modelled for patients with UC and those with CD with a shared interindividual variance term and shared covariate effects except for partial Mayo score and CDAI score. The reference individual weighs 70 kg; is 40 years old; has an albumin level of 4 g/dL, a fecal calprotectin level of 700 mg/kg, a CDAI score of 300 (for patient with CD), a partial Mayo score of 6 (for patient with UC), a diagnosis of UC (for *V* ~c~ parameter), and no concomitant therapy use; and is anti‐drug antibody negative and tumour necrosis factor‐α antagonist therapy naïve.

John Wiley & Sons, Ltd

![Distribution of individual vedolizumab linear clearance (*CL*~L~) estimates from the final population pharmacokinetic model in patients with UC and patients with CD.](APT-42-188-g003){#apt13243-fig-0003}

The residual error (unexplained random residual variability in the model) was 23.5% (% CV), which is considered relatively small (Table [2](#apt13243-tbl-0002){ref-type="table-wrap"}). Standard deviations and shrinkage estimates of interindividual random effects are presented in Table S3. Goodness‐of‐fit plots from the final population pharmacokinetic model are presented in Figures [4](#apt13243-fig-0004){ref-type="fig"} and S1. These plots indicate that the full covariate pharmacokinetic model was consistent with the observed data and no systematic bias was evident.

![Goodness‐of‐fit plots: observed vedolizumab serum concentration vs. population and individual predicted vedolizumab concentration from the final population pharmacokinetic model. Values are shown as points with a dashed pink loess trend line through the data. A line of identity (solid black) is shown for reference.](APT-42-188-g004){#apt13243-fig-0004}

The relative changes in *CL* ~L~ for a reference patient with various covariate values are illustrated in Figure [5](#apt13243-fig-0005){ref-type="fig"}. The impact of these covariates on *CL* ~L~ was evaluated univariately. The point estimates and 95% CDIs for the effects of covariates on *CL* ~L~ are presented in Table S4. In general, the 95% CDIs were narrow indicating that the effect of each covariate on vedolizumab *CL* ~L~ was well defined. Only the effects of albumin and body weight at extreme values had the potential to be clinically meaningful (effect sizes greater than ±25%). The *CL* ~L~ values for patients with albumin levels of 4.7 and 3.2 g/dL were approximately 0.8 and 1.3 times, respectively, that of the reference patient (albumin, 4 g/dL) (Figure [5](#apt13243-fig-0005){ref-type="fig"}). The *CL* ~L~ values for patients of 40 and 120 kg were approximately 0.8 and 1.2 times, respectively, that of the reference patient (weight, 70 kg) (Figure [5](#apt13243-fig-0005){ref-type="fig"}). A patient of 120 kg with a serum albumin concentration of 4.0 g/dL had a 19% probability of having a *CL* ~L~ value greater than the pre‐specified criterion for clinical significance. When evaluated across a representative range of covariate values and categories, the effects of faecal calprotectin, CDAI score, partial Mayo score, age, prior TNF--α antagonist therapy status, ADA status, and concomitant therapy use on vedolizumab *CL* ~L~ were not considered clinically relevant as the covariate effect sizes were less than ±25% from the reference values (Figure [5](#apt13243-fig-0005){ref-type="fig"} and Table S4). In addition, the 95% CDIs for these covariate effects contained the null effect value.

![Effect of covariates on vedolizumab linear clearance (*CL*~L~). Each point and line represent the median and 95% credible interval, respectively, of the Bayesian posterior distribution of normalised samples of vedolizumab *CL*~L~ adjusted for the covariate. The reference individual weighs 70 kg; is 40 years old; has an albumin level of 4 g/dL, a faecal calprotectin level of 700 mg/kg, a CDAI score of 300 (for patient with CD), a partial Mayo score of 6 (for patient with UC), and no concomitant therapy use; and is ADA negative and TNF‐*α* antagonist therapy naïve. Albumin: 2.7, 3.2, 3.7, 4.2 and 4.7 g/dL represent the 6th, 18th, 70th, 85th, and 98.5th percentiles, respectively, of baseline albumin levels for patients in GEMINI 1, 2, and 3. Weight: 40, 60, 80, 100, and 120 kg represent the 1.5th, 30th, 71st, 92nd and 98th percentiles, respectively, of baseline weight values for patients in GEMINI 1, 2, and 3. The vertical black line is drawn at the reference point estimate, and the shaded region is ± 25% of the reference point estimate chosen to represent an uncertainty range of clinical unimportance.](APT-42-188-g005){#apt13243-fig-0005}

The final population pharmacokinetic model was rerun with all covariate effects and pharmacokinetic parameters fixed to estimates from the final model (interindividual variances were re‐estimated), and any remaining effects of sex on *CL* ~L~ and *V* ~c~ were quantified. The results of this analysis suggest that, after adjustment for other predictors of vedolizumab *CL* ~L~, the *CL* ~L~ and *V* ~c~ values were approximately 10% lower and 6% lower, respectively, for a female patient compared with a male patient. However, these effects were not considered clinically relevant as the covariate effect sizes were less than ± 25% from the reference values (male patient). Addition of the sex effect explained approximately 4.2% and 6.0% of the unexplained interindividual variability in *CL* ~L~ and *V* ~c~, respectively.

The final population pharmacokinetic model also was re‐run to estimate any remaining effect of CRP on *CL* ~L~. The results suggest that, after adjustment for other predictors of vedolizumab *CL* ~L~ (such as albumin), the effect of CRP on *CL* ~L~ was not clinically relevant as the covariate effect size was less than ± 25% from the reference value (CRP, 11 mg/dL). The addition of the CRP effect explained \<1% of the unexplained interindividual variability in *CL* ~L~.

For patients with UC, the effect of Mayo endoscopic subscore was evaluated graphically by plotting individual *CL* ~L~ estimates from the final population pharmacokinetic model by endoscopic subscore at week 6 (Figure [6](#apt13243-fig-0006){ref-type="fig"}). From this analysis, at week 6 (end of induction treatment), patients with an endoscopic subscore of 3 had on average 25% higher *CL* ~L~ than patients with an endoscopic subscore of 0.

![Individual vedolizumab linear clearance (*CL*~L~) estimates by Mayo endoscopic subscore at the end of induction (week 6) for patients with UC (GEMINI 1). Midlines represent medians. Box limits represent 25th and 75th percentiles. Whiskers (error bars) represent highest and lowest points within 1.5 × interquartile range. Individual points represent outliers.](APT-42-188-g006){#apt13243-fig-0006}

### Pharmacokinetic model evaluation {#apt13243-sec-0018}

The final population pharmacokinetic model and parameter estimates were evaluated with a predictive check method and Bayesian 95% CDIs derived from the posterior probability distributions. The basic premise of a predictive check is that a model and parameters derived from an observed data set should produce simulated data that are similar to the original observed data. The predictive check plots demonstrated overall good agreement between the observed and simulated data (Figures S2--S4). The precision of the parameter estimates was assessed by evaluating the Bayesian 95% CDIs (Tables [2](#apt13243-tbl-0002){ref-type="table-wrap"}, S2, and S4). Overall, the structural pharmacokinetic model parameters, covariate effects and variance parameters were estimated with good precision.

Pharmacokinetic‐pharmacodynamic data set {#apt13243-sec-0019}
----------------------------------------

The vedolizumab population pharmacokinetic‐pharmacodynamic data set was composed of 593 individuals contributing a total of 2442 evaluable MAdCAM‐1 observations. The data set consisted of 297 patients with UC and 296 patients with CD (from the phase 2 study and phase 3 GEMINI 1 and 2 studies).

During the analysis, the log‐transformed values of MAdCAM‐1 (free α~4~β~7~ receptors not blocked by vedolizumab) were modelled. A plot of observed MAdCAM‐1 measurements (percentage of free α~4~β~7~ receptors) vs. observed vedolizumab serum concentrations for patients with UC and CD from GEMINI 1 and 2, respectively, is presented in Figure [7](#apt13243-fig-0007){ref-type="fig"}. Plots of observed MAdCAM‐1 measurements vs. time by treatment regimen for patients with UC and CD in GEMINI 1 and 2, respectively, are presented in Figure [8](#apt13243-fig-0008){ref-type="fig"}. The percentage of free α~4~β~7~ receptors declined rapidly after the first dose and this reduction was maintained during repeated IV infusions of vedolizumab 300 mg.

![Receptor (α~4~β~7~) saturation plot: observed MAdCAM‐1 vs. observed vedolizumab serum concentration in patients with UC (GEMINI 1) and patients with CD (GEMINI 2). Baseline data are included.](APT-42-188-g007){#apt13243-fig-0007}

![Observed MAdCAM‐1 vs. time for patients with UC (GEMINI 1) and patients with CD (GEMINI 2). Upper left panel: patients received placebo during induction and maintenance; upper right panel: patients received 2 doses of vedolizumab 300 mg during induction and vedolizumab 300 mg every 4 weeks (Q4W) during maintenance; lower left panel: patients received 2 doses of vedolizumab 300 mg during induction and vedolizumab 300 mg every 8 weeks (Q8W) during maintenance; lower right panel: patients received 2 doses of vedolizumab 300 mg during induction and placebo during maintenance.](APT-42-188-g008){#apt13243-fig-0008}

Population pharmacokinetic‐pharmacodynamic modelling results {#apt13243-sec-0020}
------------------------------------------------------------

Structural parameter estimates from the population pharmacokinetic‐pharmacodynamic model are presented in Table [3](#apt13243-tbl-0003){ref-type="table-wrap"}; parameters were estimated with adequate precision. An attempt was made to model a placebo effect, but the estimated effect was negligible. The lack of an apparent placebo effect was consistent with the observed MAdCAM‐1 data in placebo--treated patients.

###### 

Parameter estimates from base MAdCAM‐1 population pharmacokinetic--pharmacodynamic model for vedolizumab

  Parameter                                                            Estimate              Percent relative S.E.
  -------------------------------------------------------------------- --------------------- -----------------------
  Baseline MAdCAM‐1 percent binding (*E* ~0~)                          12.1%                 3.49
  Vedolizumab serum concentration at half‐maximum effect (*EC* ~50~)   0.093 μg/mL           25.8
  Maximum effect (*E* ~max~)                                           0.959                 0.503
  Hill‐coefficient or slope factor (γ)                                 0.801                 11.1
  Exponential residual error variance (σ^2^ ~exp~)                     0.613 (% CV = 78.3)   10.4

CV, coefficient of variation; S.E., standard error.

John Wiley & Sons, Ltd

The base model provided a reasonable description of the data as judged by visual inspection of diagnostic plots (Figure S5), but some deficiencies in the model were noted. Variance parameter estimates were indicative of moderate to large unexplained interindividual and residual variability, with estimates of 41.8% CV for *E* ~0~, 0.551 (SD logistic distribution) for *E* ~max~, and 78.3% CV for the exponential residual error variance (σ^2^ ~exp~) (Table [3](#apt13243-tbl-0003){ref-type="table-wrap"}).

Discussion {#apt13243-sec-0021}
==========

We developed a population pharmacokinetic model for vedolizumab administered IV to healthy volunteers and patients with moderately to severely active UC and CD, using data collected in clinical trials with identical designs and sampling schedules. These design features allowed the direct comparison of the disposition and pharmacokinetic variability in vedolizumab in patients with UC and patients with CD. The estimated half‐life of vedolizumab was not different between the 2 diseases and was 25.5 days for the reference patient \[individual estimates ranged from 14.6 to 36.0 days (5th and 95th percentiles respectively)\], which is typical of human IgG~1~ (25 days) and of monoclonal antibodies of the IgG~1~ subclass. This half‐life is longer than values for other currently marketed biologic treatments for UC and CD. Clinicians should be aware of the relatively long half‐life of vedolizumab in circumstances when it is desirable to minimise exposure to the drug.

A 2‐compartment pharmacokinetic model consisting of parallel clearance via a nonlinear pathway (*CL* ~NL~) and a linear pathway (*CL* ~L~) from the central compartment was selected as the base model for vedolizumab. The nonlinear elimination was best described by Michaelis--Menten elimination.[15](#apt13243-bib-0015){ref-type="ref"} Physiologically, the nonlinear pathway is thought to be due to clearance by saturable, target‐mediated mechanisms such as receptor‐mediated endocytosis. In contrast, the linear pathway represents components that are nonsaturable at therapeutic concentrations, such as Fc‐mediated elimination. Parallel elimination is typical of monoclonal antibodies with disposition that is affected by binding to the target, in the case of vedolizumab, the α~4~β~7~ integrin on circulating T lymphocytes.[16](#apt13243-bib-0016){ref-type="ref"} Similar target‐mediated drug disposition properties have been reported for efalizumab, tocilizumab and cetuximab.[17](#apt13243-bib-0017){ref-type="ref"}, [18](#apt13243-bib-0018){ref-type="ref"}, [19](#apt13243-bib-0019){ref-type="ref"} In contrast, the elimination of TNF‐α antagonists, such as infliximab and golimumab, was best described by a single linear elimination pathway.[20](#apt13243-bib-0020){ref-type="ref"}, [21](#apt13243-bib-0021){ref-type="ref"}, [22](#apt13243-bib-0022){ref-type="ref"} TNF‐α exists in both soluble and membrane‐bound forms and is present in abnormally high concentrations in serum and gut mucosa in patients with IBD. The localization of TNF‐α in inflammatory tissues may make it difficult to rapidly achieve target saturation at therapeutic concentrations because of slow redistribution of the drug from plasma to the target sites.[23](#apt13243-bib-0023){ref-type="ref"} Furthermore, variability in TNF‐α concentrations in different compartments results in drug redistribution, with possible effects on pharmacokinetic‐efficacy/safety relationships of TNF‐α antagonists.[24](#apt13243-bib-0024){ref-type="ref"} The clinical implications of these differences in elimination pathways are not currently understood.

The vedolizumab *CL* ~L~ values estimated from the pharmacokinetic model are consistent with those of other monoclonal antibodies that are administered intravenously.[18](#apt13243-bib-0018){ref-type="ref"}, [20](#apt13243-bib-0020){ref-type="ref"}, [22](#apt13243-bib-0022){ref-type="ref"} Although some authors have reported that the clearance of monoclonal antibodies could be affected by IBD type,[3](#apt13243-bib-0003){ref-type="ref"} no apparent differences were observed in the *CL* ~L~ of vedolizumab in patients with UC and those with CD. Vedolizumab *CL* ~L~ for a 40‐year‐old, 70‐kg patient with a serum albumin concentration of 4 g/dL was 0.159 L/day for a patient with UC and 0.155 L/day for a patient with CD.

We evaluated the potential effects of intrinsic and extrinsic covariates (body weight, age, albumin, faecal calprotectin, CDAI score, partial Mayo score, concomitant therapy use, ADA status, and prior TNF‐α antagonist therapy status) on vedolizumab *CL* ~L~. Extreme values of albumin had important effects on vedolizumab *CL* ~L~. Specifically, *CL* ~L~ increased as albumin concentrations decreased. Albumin concentrations below 3.2 g/dL, for a patient of 70 kg, were associated with increased vedolizumab *CL* ~L~ that was greater than the pre‐specified criterion for clinical significance. Similar association of low albumin concentrations with increased clearance has been reported in population pharmacokinetic analyses of other monoclonal antibodies.[21](#apt13243-bib-0021){ref-type="ref"}, [25](#apt13243-bib-0025){ref-type="ref"} Although the mechanism of this interaction is incompletely understood, the neonatal Fc receptor (FcRn)--which is expressed in a wide variety of cells and tissues throughout the body, including the vascular endothelium, monocytes, macrophages, dendritic cells, hepatocytes and epithelial cells of the intestine, renal proximal convoluted tubules, and upper airways--facilitates IgG and albumin homeostasis by salvaging these molecules from proteolysis and recycling them into the central circulatory system. It has been postulated that decreased expression and/or activity of FcRn in patients with IBD results in low albumin and IgG concentrations due to less efficient salvage of these proteins; the net result is increased antibody clearance.[26](#apt13243-bib-0026){ref-type="ref"} However, this hypothesis has not been proven. Another possible explanation is that inflammation of the gastrointestinal tract in patients with IBD can result in an unconventional route of elimination. Specifically, in the setting of severe colitis, patients may develop a protein‐losing colopathy in which large amounts of protein are lost from the luminal surface. Albumin may therefore serve as a surrogate marker for loss of endogenous IgG and monoclonal antibodies via this pathway. This hypothesis is in part supported by observations in patients with severe colitis treated with infliximab, in whom concentrations of the monoclonal antibody were high in the stool and low in serum; successful treatment was associated with resolution of this phenomenon.[27](#apt13243-bib-0027){ref-type="ref"} Vedolizumab concentrations in faeces were not measured during the GEMINI trials, precluding us from evaluating this hypothesis.

The second important covariate identified was body weight, which was positively correlated with vedolizumab *CL* ~L~. A patient of 120 kg with a serum albumin concentration of 4.0 g/dL had a 19% probability of having *CL* ~L~ greater than the pre‐specified criterion for clinical significance. Measures of body size are the most commonly identified covariates influencing the pharmacokinetics of therapeutic monoclonal antibodies.[25](#apt13243-bib-0025){ref-type="ref"} The impact of body weight on vedolizumab *CL* ~L~ is consistent with that reported in population pharmacokinetic analyses of other therapeutic monoclonal antibodies.[25](#apt13243-bib-0025){ref-type="ref"}

Other potential covariates had lesser effects on vedolizumab *CL* ~L~ than weight and albumin in the current analysis. Patients with UC who had lower Mayo endoscopic subscores had, on average, lower vedolizumab *CL* ~L~ and, therefore, higher serum concentrations than patients who had higher endoscopic subscores. This finding is consistent with what has been reported for TNF‐α antagonists.[4](#apt13243-bib-0004){ref-type="ref"}, [28](#apt13243-bib-0028){ref-type="ref"}, [29](#apt13243-bib-0029){ref-type="ref"}, [30](#apt13243-bib-0030){ref-type="ref"} However, these results should be interpreted with caution as it is possible that the relationship between vedolizumab *CL* ~L~ and endoscopic subscore is not causal but merely reflects the association between drug‐losing enteropathy and mucosal healing.

Intensity of inflammation has been reported as a positive predictor of clearance for other monoclonal antibodies.[3](#apt13243-bib-0003){ref-type="ref"} A *post hoc* exploratory analysis revealed that, after accounting for the effects of other covariates (such as albumin) in the existing pharmacokinetic model, the remaining effect of CRP on vedolizumab *CL* ~L~ is not clinically relevant and explained less than 1% of the unexplained interindividual variability in *CL* ~L~. Therefore, as albumin and CRP were strongly correlated, any potential effect of CRP on vedolizumab *CL* ~L~ was already accounted for in the model by incorporating albumin. Similar results have been reported recently by Wade at al. for certolizumab pegol in patients with CD.[31](#apt13243-bib-0031){ref-type="ref"} In contrast, high CRP concentrations were strongly associated with increased clearance of anti‐TNF‐*α* monoclonal antibodies in the literature; however, effects of covariates such as albumin that appear to be correlated with inflammatory markers in patients with IBD were not investigated in these analyses.[3](#apt13243-bib-0003){ref-type="ref"}

The development of ADAs has been reported to increase infliximab clearance.[21](#apt13243-bib-0021){ref-type="ref"} In the current analysis, the presence of ADAs was estimated to increase vedolizumab *CL* ~L~ by only 12%. Inferences regarding this impact are limited by the low incidence of ADAs observed in the GEMINI trials.[8](#apt13243-bib-0008){ref-type="ref"}, [9](#apt13243-bib-0009){ref-type="ref"}, [10](#apt13243-bib-0010){ref-type="ref"} In the few patients who were persistently positive for ADAs in these studies, vedolizumab trough concentrations were below the limit of quantification. We believe that sensitization of patients to monoclonal antibodies is an important cause of treatment failure and that vedolizumab is not unique in this regard.

The current analysis showed no clinically meaningful impact of prior TNF‐α antagonist therapy status, concomitant medication use, age (from 18 to 78 years old), and disease activity on vedolizumab *CL* ~L~. The lack of association between prior TNF‐α antagonist therapy status and vedolizumab *CL* ~L~ is interesting, especially given that lack of prior TNF‐α antagonist therapy use was associated with a higher probability of clinical remission or response in vedolizumab‐treated patients with UC and those with CD.[11](#apt13243-bib-0011){ref-type="ref"}, [12](#apt13243-bib-0012){ref-type="ref"} Taken together, these observations suggest that the impact of prior TNF‐α antagonist therapy use on vedolizumab efficacy is not related to any effect on vedolizumab *CL* ~L.~

The lack of an effect of thiopurines and methotrexate on vedolizumab *CL* ~L~ differs from effects seen on TNF‐α antagonists in patients with UC and CD and in patients with rheumatoid arthritis, where co‐administration of these agents is associated with higher trough concentrations and lower clearance of TNF‐α antagonists.[32](#apt13243-bib-0032){ref-type="ref"} The mechanism by which antimetabolites increase concentrations of biologic drugs is not well understood; however, modulation of Fcγ receptor expression is one possible explanation. For example, methotrexate is known to down‐regulate Fcγ receptors on monocytes and other Fc‐receptor subtypes. Another possible explanation is that the prevention of ADA development could increase drug exposure by reducing immune‐mediated drug clearance. The reason behind the lack of effect of concomitant medications on vedolizumab *CL* ~L~ is not currently understood. A sensitivity analysis was performed to determine whether the rate of concomitant medication use in the vedolizumab population pharmacokinetic data set was sufficient to achieve at least 80% power to detect no drug interaction, as recommended by the Population Pharmacokinetic Therapeutic Protein--Drug Interaction (PK TPDI) Working Group.[33](#apt13243-bib-0033){ref-type="ref"} This analysis revealed that the data set met the sample size requirements to ensure at least 80% power and confirmed that vedolizumab *CL* ~L~ was not impacted by concomitant use of azathioprine, mercaptopurine, methotrexate or aminosalicylates.[34](#apt13243-bib-0034){ref-type="ref"}

Interestingly, α~4~β~7~ receptor saturation, as measured in the MAdCAM‐1 assay, was maintained at vedolizumab concentrations considered subtherapeutic, raising the question of whether receptor saturation is necessary but not sufficient for clinical efficacy. The *EC* ~50~ estimate from the population pharmacokinetic‐pharmacodynamic model was 0.093 μg/mL, suggesting that full saturation is reached at a vedolizumab serum concentration of approximately 1 μg/mL. Exposure‐efficacy data indicated that vedolizumab concentrations below 17 and 15 μg/mL at induction were associated with efficacy similar to placebo in patients with UC and those with CD, respectively.[8](#apt13243-bib-0008){ref-type="ref"}, [9](#apt13243-bib-0009){ref-type="ref"} This discrepancy might be explained by the fact that the MAdCAM‐1 assay measures α~4~β~7~ saturation in circulating T‐cells, or may be due to a slow onset of action of the drug. The MAdCAM‐1 assay is insensitive to dose and should not be used for dose selection. Further studies to evaluate the relative pharmacodynamic contributions of α~4~β~7~ receptor blockade in the peripheral blood vs. in the tissue compartment are a research priority.

In conclusion, a population model characterising the pharmacokinetic properties of vedolizumab was successfully developed for patients with UC and CD. The modelling results suggested that vedolizumab *CL* ~L~ was similar in patients with UC and those with CD. Albumin and body weight were identified as predictors of vedolizumab *CL* ~L~, but the effects of these covariates were only considered clinically meaningful at extreme values. Surprisingly, concomitant use of immunosuppressants had no clinically relevant impact on vedolizumab *CL* ~L~, a finding that contrasts with the well--established relationship between immunogenicity and TNF‐α antagonist concentrations. This analysis supports use of fixed dosing with vedolizumab in patients with UC and those with CD.
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